medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-26-13-19medalphabet-2841Research ArticleСтатьиМетастатическое поражение печени при эстроген-рецептор-положительном HER 2-отрицательном раке молочной железы. Рибоциклиб – терапия, меняющая прогноз.Liver metastasis in estrogen receptor-positive HER 2-negative breast cancer. Ribociclib as prognosis-changing therapyhttps://orcid.org/0000-0001-5289-7866ЛубенниковаЕ. В.LubennikovaE. V.

Лубенникова Елена Владимировна, к. м. н., старший научный сотрудник отделения лекарственных методов лечения № 1

Москва

Lubennikova Elena V., PhD Med, senior researcher of Dept of Medicinal Methods of Treatment № 1

Moscow

lubennikova@yandex.ruhttps://orcid.org/0000-0002-0635-9343ЦареваА. С.TsarevaA. S.

Царева Анастасия Сергеевна, врач-ординатор отделения лекарственных методов лечения № 1

Москва

Tsareva Anastasiya S., resident oncologist of Dept of Medicinal Methods of Treatment № 1

Moscow

tsarevaas1997@yandex.ruhttps://orcid.org/0000-0001-5993-7998КузнецоваА. А.KuznetsovaA. A.

Кузнецова Анна Алексеевна, врач-онколог научно- консультативного отделения

Москва

Kuznetsova Anna.A., oncologist at Dept of Scientific Advisory

Moscow

misuenno@gmail.comhttps://orcid.org/0000-0001-7728-9533АртамоноваЕ. В.ArtamonovaE. V.

Артамонова Елена Владимировна, д. м. н., зав. отделением лекарственных методов лечения № 1; профессор кафедры онкологии и лучевой терапии; зав. кафедрой онкологии и торакальной хирургии

Москва

Artamonova Elena V., DM Sci (habil.), head of the Dept of Medicinal Methods of Treatment № 1; professor at Dept of Oncology and Radiation; head of the Dept of Oncology and Thoracic Surgery

Moscow

artamonovae@mail.ruФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава РоссииРоссияRussian Oncological Scientific Centre n. a. N. N. BlokhinRussian FederationФГБУ «Российский онкологический научный центр имени Н. Н. Блохина» Минздрава России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Минздрава России; ФУВ ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М. Ф. Владимирского»РоссияRussian Oncological Scientific Centre n. a. N. N. Blokhin; Russian National Research Medical University n. a. N. I. Pirogov; Moscow Regional Research Clinical Institute n. a. M. F. VladimirskyRussian Federation202223112022026Диагностика и онкотерапия (3)1319Copyright © Лубенникова Е.В., Царева А.С., Кузнецова А.А., Артамонова Е.В., 20222022Лубенникова Е.В., Царева А.С., Кузнецова А.А., Артамонова Е.В.Lubennikova E.V., Tsareva A.S., Kuznetsova A.A., Artamonova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2841

Продолжительность жизни больных метастатическим люминальным HER 2-отрицательным РМЖ долгие годы стагнировала на уровне 40 месяцев. Внедрение в практику ингибиторов CDK4/6 изменило стандарты терапии, обеспечив не только значимое увеличение времени без прогрессирования при сохранении высокого качества жизни, но и достоверно повысив общую выживаемость. Наличие метастазов в печени определяет крайне неблагоприятный прогноз, при ГР+HER 2-мРМЖ сокращая продолжительность жизни до медианы в 21 месяц. Комбинированная с рибоциклибом эндокринотерапия достоверно повысила показатели общей выживаемости в среднем на год, достигнув медиан 36,1 и 46,5 месяца в зависимости от линии лечения. Данная публикация посвящена метастатическому поражению печени при РМЖ, в частности при люминальном HER 2-отрицательном подтипе. Рассмотрены эпидемиологические аспекты, оценены возможности современной системной терапии. Представлен клинический случай успешной терапии рибоциклибом у молодой пациентки с поражением печени.

The life expectancy of patients with metastatic luminal HER 2-negative breast cancer has stagnated at the level of 40 months for many years. The introduction of CDK4/6 inhibitors into practice has changed the standards of therapy, providing not only a significant increase in the time without progression while maintaining a high quality of life, but also significantly increasing overall survival. The presence of liver metastases determines an extremely unfavorable prognosis, with GH+HER 2-mBC reducing life expectancy to a median of 21 months. Endocrine therapy combined with ribociclib significantly increased overall survival rates on average per year, reaching medians of 36.1 and 46.5 months, depending on the line of treatment. This publication is devoted to liver metastases in breast cancer, in particular in the luminal HER 2-negative subtype. Epidemiological aspects are considered, the possibilities of modern systemic therapy are evaluated. A clinical case of successful therapy with ribociclib in a young patient with liver damage is presented.

рибоциклибметастатический рак молочной железылюминальный рак молочной железыэндокринотерапияэндокринорезистентностьметастазы в печениингибиторы CDК4/6ribociclibmetastatic breast cancerluminal breast cancerendocrine therapyendocrine resistanceliver metastasesCDK4/6 inhibitorsReferencesSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A cancer journal for clinicians. 2019; 69 (1): 7–34. https://doi.org/10.3322/caac.21551Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A cancer journal for clinicians. 2019; 69 (1): 7–34. https://doi.org/10.3322/caac.21551Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: A cancer journal for clinicians. 2019; 69 (5): 363–385. https://doi.org/10.3322/caac.21565.Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: A cancer journal for clinicians. 2019; 69 (5): 363–385. https://doi.org/10.3322/caac.21565.Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. Journal of internal medicine. 2013; 274 (2): 113–126. https://doi.org/10.1111/joim.12084.Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. Journal of internal medicine. 2013; 274 (2): 113–126. https://doi.org/10.1111/joim.12084.Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine. 2012; 366 (2): 109–119. https://doi.org/10.1056/NEJMoa1113216Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine. 2012; 366 (2): 109–119. https://doi.org/10.1056/NEJMoa1113216Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status JNCI: Journal of the National Cancer Institute. 2014; 106 (5). https://doi.org/10.1093/jnci/dju055Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status JNCI: Journal of the National Cancer Institute. 2014; 106 (5). https://doi.org/10.1093/jnci/dju055Parise CA, Bauer KR, Brown MM, et al. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. The Breast Journal. 2009; 15 (6): 593–602. https://doi.org/10.1111/j.1524–4741.2009.00822.xParise CA, Bauer KR, Brown MM, et al. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. The Breast Journal. 2009; 15 (6): 593–602. https://doi.org/10.1111/j.1524–4741.2009.00822.xLobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast 2-positive subtype is associated with cancer subtypes: the hormone receptor/HER the most favorable outcome. Breast cancer research and treatment. 2013; 141 (3): 507–514. https://doi.org/10.1007/s10549–013–2711-yLobbezoo DJA, van Kampen RJW, Voogd AC, et al. Prognosis of metastatic breast 2-positive subtype is associated with cancer subtypes: the hormone receptor/HER the most favorable outcome. Breast cancer research and treatment. 2013; 141 (3): 507–514. https://doi.org/10.1007/s10549–013–2711-yDuan XF, Dong NN, Zhang T, et al. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. International journal of clinical oncology. 2013; 18 (1): 26–32. https://doi.org/10.1007/s10147–011–0336-xDuan XF, Dong NN, Zhang T, et al. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer. International journal of clinical oncology. 2013; 18 (1): 26–32. https://doi.org/10.1007/s10147–011–0336-xSihto H, Lundin J, Lundin M, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research. 2011; 13 (5): 1–11. https://doi.org/10.1186/bcr2944Sihto H, Lundin J, Lundin M, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Research. 2011; 13 (5): 1–11. https://doi.org/10.1186/bcr2944N. C. Turner, R. S. Finn, M. Martin, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 2018; 29 (3): 669–680. https://doi.org/10.1093/annonc/mdx797N. C. Turner, R. S. Finn, M. Martin, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 2018; 29 (3): 669–680. https://doi.org/10.1093/annonc/mdx797Zhao HY, Gong Y, Ye FG, et al. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Management and Research. 2018; 10: 5937–5950. https://doi.org/10.2147/CMAR.S178395.Zhao HY, Gong Y, Ye FG, et al. Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: a population-based study. Cancer Management and Research. 2018; 10: 5937–5950. https://doi.org/10.2147/CMAR.S178395.Diamond J. R., Finlayson C. A., Borges V. F. et al. Hepatic complications of breast cancer. The Lancet Oncology. 2009; 10 (6): 615–621. https://doi.org/10.1016/S1470–2045 (09)70029–4Diamond J. R., Finlayson C. A., Borges V. F. et al. Hepatic complications of breast cancer. The Lancet Oncology. 2009; 10 (6): 615–621. https://doi.org/10.1016/S1470–2045 (09)70029–4Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clinical Breast Cancer. 2013; 13 (2): 88–94. https://doi.org/10.1016/j.clbc.2012.11.001Berman AT, Thukral AD, Hwang WT, et al. Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. Clinical Breast Cancer. 2013; 13 (2): 88–94. https://doi.org/10.1016/j.clbc.2012.11.001Cummings MC, Simpson PT, Reid LE, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. The Journal of Pathology. 2014; 232 (1): 23–31. https://doi.org/10.1002/path.4288Cummings MC, Simpson PT, Reid LE, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. The Journal of Pathology. 2014; 232 (1): 23–31. https://doi.org/10.1002/path.4288Ji L., Cheng L., Zhu X., et al. Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer. 2021; 21 (1): 1–15. https://doi.org/10.1186/s12885–021–07968–5Ji L., Cheng L., Zhu X., et al. Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer. 2021; 21 (1): 1–15. https://doi.org/10.1186/s12885–021–07968–5Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast cancer research and treatment. 2006; 97 (3): 237–244. https://doi.org/10.1007/s10549–005–9117–4Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast cancer research and treatment. 2006; 97 (3): 237–244. https://doi.org/10.1007/s10549–005–9117–4Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. British Journal of Cancer. 2003; 89 (2): 284–290. https://doi.org/10.1038/sj.bjc.6601038Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. British Journal of Cancer. 2003; 89 (2): 284–290. https://doi.org/10.1038/sj.bjc.6601038Surveillance, Epidemiology, and End Results Program, Research Data (1975–2016), National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Surveillance Research Program (SRP), released April 2019, based on the November 2018 submission [https://seer.cancer.gov/].Surveillance, Epidemiology, and End Results Program, Research Data (1975–2016), National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS), Surveillance Research Program (SRP), released April 2019, based on the November 2018 submission [https://seer.cancer.gov/].Xie J, Xu Z. A population-based study on liver metastases in women with newly diagnosed breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2019; 28 (2): 283–292. https://doi.org/10.1158/1055–9965.EPI-18–0591Xie J, Xu Z. A population-based study on liver metastases in women with newly diagnosed breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2019; 28 (2): 283–292. https://doi.org/10.1158/1055–9965.EPI-18–0591Shah AN, Cristofanilli M. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Current treatment options in oncology. 2017; 18 (1): 1–16. https://doi.org/10.1007/s11864–017–0443–7Shah AN, Cristofanilli M. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Current treatment options in oncology. 2017; 18 (1): 1–16. https://doi.org/10.1007/s11864–017–0443–7Mouridsen H., Sun, Y., Gershanovich, M, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. The Oncologist. 200; 9 (5): 489–496. https://doi.org/10.1634/theoncologist.9–5–489Mouridsen H., Sun, Y., Gershanovich, M, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. The Oncologist. 200; 9 (5): 489–496. https://doi.org/10.1634/theoncologist.9–5–489Bonneterre J., Buzdar A., Nabholtz J.M.A., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis. Cancer. 2001; 92 (9): 2247–2258. https://doi.org/10.1002/1097–0142 (20011101)92:9<2247:: AID-CNCR1570>3.0.CO;2-YBonneterre J., Buzdar A., Nabholtz J.M.A., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: Results of two randomized trials designed for combined analysis. Cancer. 2001; 92 (9): 2247–2258. https://doi.org/10.1002/1097–0142 (20011101)92:9<2247:: AID-CNCR1570>3.0.CO;2-YParidaens R. J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology. 2008; 26 (30), 4883. https://doi.org/10.1200/JCO.2007.14.4659Paridaens R. J., Dirix L.Y., Beex L.V., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology. 2008; 26 (30), 4883. https://doi.org/10.1200/JCO.2007.14.4659Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 2016; 388 (10063): 2997–3005. https://doi.org/10.1016/S0140–6736(16)32389–3Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. The Lancet. 2016; 388 (10063): 2997–3005. https://doi.org/10.1016/S0140–6736(16)32389–3He M, Li JJ, Zuo WJ, et al. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. Cancer medicine. 2019; 8 (14): 6212–6220. https://doi.org/10.1002/cam4.2453He M, Li JJ, Zuo WJ, et al. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. Cancer medicine. 2019; 8 (14): 6212–6220. https://doi.org/10.1002/cam4.2453Cersosimo RJ. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy. 2019; 76 (16): 1183–1202. https://doi.org/10.1093/ajhp/zxz121Cersosimo RJ. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. American Journal of Health-System Pharmacy. 2019; 76 (16): 1183–1202. https://doi.org/10.1093/ajhp/zxz121Lamb R., Lehn S., Rogerson L. et al. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptordependent divergent functions in breast cancer migration and stem cell-like activity. Cell cycle. 2013; 12 (15): 2384–2394. https://doi.org/10.4161/cc.25403Lamb R., Lehn S., Rogerson L. et al. Cell cycle regulators cyclin D1 and CDK4/6 have estrogen receptordependent divergent functions in breast cancer migration and stem cell-like activity. Cell cycle. 2013; 12 (15): 2384–2394. https://doi.org/10.4161/cc.25403Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine. 2016; 375 (20): 1925–1936. https://doi.org/10.1056/NEJMoa1607303Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine. 2016; 375 (20): 1925–1936. https://doi.org/10.1056/NEJMoa1607303Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England journal of medicine. 2016; 375 (18): 1738–1748. https://doi.org/10.1056/NEJMoa1609709.Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. New England journal of medicine. 2016; 375 (18): 1738–1748. https://doi.org/10.1056/NEJMoa1609709.Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology. 2017; 35 (32): 3638–3646. https://doi.org/10.1200/JCO.2017.75.6155Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. Journal of Clinical Oncology. 2017; 35 (32): 3638–3646. https://doi.org/10.1200/JCO.2017.75.6155Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine. 2022; 386 (10): 942–950. https://doi.org/10.1056/NEJMoa2114663Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. New England Journal of Medicine. 2022; 386 (10): 942–950. https://doi.org/10.1056/NEJMoa2114663Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. New England Journal of Medicine. 2019; 381 (4): 307–316. https://doi.org/10.1056/NEJMoa1903765Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. New England Journal of Medicine. 2019; 381 (4): 307–316. https://doi.org/10.1056/NEJMoa1903765Tripathy D., Im S.A., Colleoni M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. The Lancet Oncology 2018; 19 (7): 904–915. https://doi.org/10.1016/S1470–2045 (18)30292–4Tripathy D., Im S.A., Colleoni M., et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial. The Lancet Oncology 2018; 19 (7): 904–915. https://doi.org/10.1016/S1470–2045 (18)30292–4Lu Y.S., Im S.A., Colleoni M., et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre-and Perimenopausal Patients with HR+/HER2– Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial Updated Overall Survival Analysis of the MONALEESA-7 Trial. Clinical Cancer Research. 2021; OF1–OF9. https://doi.org/10.1158/1078–0432.CCR‑21–3032Lu Y.S., Im S.A., Colleoni M., et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre-and Perimenopausal Patients with HR+/HER2– Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial Updated Overall Survival Analysis of the MONALEESA-7 Trial. Clinical Cancer Research. 2021; OF1–OF9. https://doi.org/10.1158/1078–0432.CCR‑21–3032Yardley DA, Chan A, Nusch A, et al. Abstract P6–18–07: Ribociclib+ endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials. Cancer Research. 2019; 79 (4): P6–18–07–P6–18–07. https://doi.org/10.1158/1538–7445.SABCS18-P6–18–07Yardley DA, Chan A, Nusch A, et al. Abstract P6–18–07: Ribociclib+ endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials. Cancer Research. 2019; 79 (4): P6–18–07–P6–18–07. https://doi.org/10.1158/1538–7445.SABCS18-P6–18–07Bardia A. et al. Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. Annals of Oncology. 2018; 29: 106–107. https://doi.org/10.1093/annonc/mdy272.320Bardia A. et al. Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis. Annals of Oncology. 2018; 29: 106–107. https://doi.org/10.1093/annonc/mdy272.320Yardley D.A., Nusch A., Yap Y.S., et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML)-3 and -7 trials. Journal of Clinical Oncology. 2020; 38 (15): 1054. https://doi.org/10.1200/JCO.2020.38.15_suppl.1054Yardley D.A., Nusch A., Yap Y.S., et al. Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML)-3 and -7 trials. Journal of Clinical Oncology. 2020; 38 (15): 1054. https://doi.org/10.1200/JCO.2020.38.15_suppl.1054Yeung C., Hilton J., Clemons M., et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours – ​a review. Cancer and Metastasis Reviews. 2016; 35 (3): 427–437. https://doi.org/10.1007/s10555–016–9631–3Yeung C., Hilton J., Clemons M., et al. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours – ​a review. Cancer and Metastasis Reviews. 2016; 35 (3): 427–437. https://doi.org/10.1007/s10555–016–9631–3Giuliano M., Schettini F., Rognoni C. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2- negative, metastatic breast cancer: a systematic review and network metaanalysis. The Lancet Oncology. 2019; 20 (10): 1360–1369. https://doi.org/10.1016/S1470–2045 (19)30420–6Giuliano M., Schettini F., Rognoni C. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2- negative, metastatic breast cancer: a systematic review and network metaanalysis. The Lancet Oncology. 2019; 20 (10): 1360–1369. https://doi.org/10.1016/S1470–2045 (19)30420–6Taylor C.W., Green S., Dalton W. S., et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. Journal of Clinical Oncology. 1998; 16 (3): 994–999. https://doi.org/10.1200/JCO.1998.16.3.994.Taylor C.W., Green S., Dalton W. S., et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. Journal of Clinical Oncology. 1998; 16 (3): 994–999. https://doi.org/10.1200/JCO.1998.16.3.994.Fasching P.A., Bardia A., Nusch A., et al. 276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,–3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer (ABC). Annals of Oncology. 2020; 31: S350–S351. https://doi.org/10.1016/j.annonc.2020.08.378Fasching P.A., Bardia A., Nusch A., et al. 276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,–3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer (ABC). Annals of Oncology. 2020; 31: S350–S351. https://doi.org/10.1016/j.annonc.2020.08.378Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of medicine. 2020; 382 (6): 514–524. https://doi.org/10.1056/NEJMoa1911149Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of medicine. 2020; 382 (6): 514–524. https://doi.org/10.1056/NEJMoa1911149

The authors declare that there are no conflicts of interest present.